LY2157299
LY2157299 is a pharmaceutical drug with 10 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
8 of 8 finished
0.0%
0 ended early
2
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Clinical Trials (10)
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
Study of LY2157299 in Japanese Participants With Cancer
A Study of LY2157299 in Healthy Participants
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10